- Conditions
- Alzheimer Disease
- Interventions
- Dimebon 20 mg po TID, Placebo po TID
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Costa Mesa, California • Encino, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 12,238
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration
- Interventions
- Zifibancimig, Ranibizumab, Port Delivery Platform
- Drug · Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more
- Conditions
- Multiple Myeloma
- Interventions
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Drug
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson Disease
- Interventions
- Deep Brain Stimulation, STN, GP Deep Brain Stimulation
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Myocardial Infarction
- Interventions
- Percutaneous Coronary Intervention (PCI), RO4905417, placebo
- Procedure · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 19 Years to 74 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
- Behavioral
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Missouri • West Orange, New Jersey
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloma
- Interventions
- cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, in vitro-treated bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 40 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Hypertension
- Interventions
- Nebivolol
- Drug
- Lead sponsor
- Mylan Bertek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Pediatric Onset Multiple Sclerosis (POMS)
- Interventions
- VR active video game intervention, Educational session, Standard Management of Physical Activity
- Device · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Asthma
- Interventions
- Verekitug (UPB-101), Placebo
- Drug
- Lead sponsor
- Upstream Bio Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 47 more
- Conditions
- Sleep-Disordered Breathing, Obstructive Sleep Apnea, Sleep Apnea, Central Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Broomfield, Colorado • Maplewood, Missouri • West Seneca, New York
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Calaspargase pegol (S95015)
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Multiple Myeloma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplant
- Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atopic Dermatitis
- Interventions
- FB825, Placebo
- Biological · Other
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more
- Conditions
- Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
- Interventions
- Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
- Drug · Procedure
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- GC33(RO5137382), Sorafenib
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- San Francisco, California • Miami, Florida • New York, New York + 2 more
- Conditions
- Atrial Fibrillation
- Interventions
- Dronedarone, Placebo (for Dronedarone)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 51 more
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- INCB007839
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hyperopia, Hyperopic Astigmatism
- Interventions
- riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off), Laser-assisted in situ keratomileusis
- Drug · Device · Procedure
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Continuous glucose monitoring system
- Device
- Lead sponsor
- Senseonics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Escondido, California • Walnut Creek, California • Renton, Washington